Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures

Leukemia Research

Volumn 30, Issue 3, 2006, Pages 286-295

  Chávez González, Antonieta ^a   Ayala Sánchez, Manuel ^b   Sánchez Valle, Elizabeth ^b   Ruiz Sánchez, Elizabeth ^c   Arana Trejo, Rosa María ^c   Vela Ojeda, Jorge ^b   Mayani, Hector ^a,d  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d D 102 ^*  (Mexico)

Author keywords

CD34+ cells; CML; IFN; IMATINIB; In vitro; Marrow transplant; Proliferation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; RECOMBINANT CYTOKINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CANCER REGRESSION; CD34 SELECTION; CELL COUNT; CELL CULTURE; CELL GROWTH; CELL KINETICS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING CELL; CONTROLLED STUDY; CONVALESCENCE; CYTOGENETICS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CULTURE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CELL PROLIFERATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PYRIMIDINES; RECOVERY OF FUNCTION; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 30144444178     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.06.028     Document Type: Article

References (43)

1. S. Faderl, M. Talpaz, and Z. Estrov The biology of chronic myeloid leukemia N Engl J Med 341 1999 164 172
2. A.L. Petzer, and E. Gunsilius Hematopoietic stem cells in chronic myeloid leukemia Arch Med Res 34 2003 496 506
3. O. Witte The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology Sem Hematol 38 Suppl. 8 2001 3 8
4. W.H. Raskind, and P.J. Fialkow The use of cell markers in the study of human hematopoietic neoplasia Adv Cancer Res 49 1987 127 167
5. A. Bedi, B.A. Zehnbauer, J.P. Barber, S.J. Sharkis, and R.J. Jones Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia Blood 83 1994 2038 2044
6. A. McGahon, R. Bissonnette, M. Schmitt, K.M. Cotter, D.R. Green, and T.G. Cotter BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death Blood 83 1994 1179 1187
7. L. Coulombel, D. Kalousek, C.J. Eaves, C.M. Gupta, and A.C. Eaves Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia N Engl J Med 308 1983 1493 1498
8. C. Udomsakdi, C.J. Eaves, B. Swolin, D.S. Reid, M.J. Barnett, and A.C. Eaves Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level Proc Natl Acad Sci USA 89 1992 6192 6196
9. F. Luna-Bautista, E. Sánchez-Valle, M. Ayala-Sánchez, M. Morales-Polanco, L. Meillon-Garcia, and L. Benitez-Bribiesca Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: effect of recombinant cytokines in Dexter-type long-term cultures Hematology 8 2003 155 163
10. + cell subpopulations from patients with chronic myeloid leukemia Leuk Res 28 2004 639 647
11. C.J. Eaves, J. Cashman, S. Wolpe, and A.C. Eaves Unresponsiveness of primitive myeloid leukemia cells to Macrophage Inflammatory Protein-1α, an inhibitor of primitive normal hematopoietic cells Proc Natl Acad Sci USA 90 1994 12015 12019
12. M.Y. Gordon, C.R. Dowding, G.P. Riley, J.M. Goldman, and M.E. Greaves Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia Nature 328 1984 342 344
13. C.M. Traycoff, B. Halstead, S. Rice, J. McMahel, and E.F. Sour Chronic myelogenous leukemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells Br J Haematol 102 1998 759 767
14. C. Sawyers Chronic myeloid leukemia N Engl J Med 340 1999 1330 1340
15. J.M. Goldman Chronic myeloid leukemia Curr Opin Hematol 4 1997 277 285
16. R. Hehlmann, H. Heimpel, J. Hasford, H.J. Kolb, H. Pralle, and D.K. Hossfeld Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia Blood 84 1994 4064 4077
17. F. Guilhot, C. Chastang, M. Michallet, A. Guerci, J.L. Harousseau, and F. Maloisel Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia N Engl J Med 337 1997 223 229
18. J.A. Hansen, T.A. Gooley, P.J. Martin, F. Appelbaum, T.R. Chauncey, and R.A. Clift Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia N Engl J Med 338 1998 962 968
19. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, and J.M. Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
20. J.M. Goldman, and B.J. Druker Chronic myeloid leukemia: current treatment options Blood 98 2001 2039 2042
21. A.W. Wognum, A.C. Eaves, and T.E. Thomas Identification and isolation of hematopoietic stem cells Arch Med Res 34 2003 461 475
22. H. Mayani, W. Dragowska, and P.M. Lansdorp Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells Blood 81 1993 3252 3258
23. + cell-enriched hematopoietic cell population from human umbilical cord blood in response to recombinant cytokines Arch Med Res 33 2002 107 114
24. T.L. Holyoake, X. Jiang, M.W. Drummond, A.C. Eaves, and C.J. Eaves Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia Leukemia 16 2002 549 558
25. A. Goga, J. McLaughlin, D.E.H. Afar, D.C. Saffran, and O.N. Witte Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene Cell 82 1995 981 988
26. T.L. Holyoake, X. Jiang, H.G. Jorgensen, S. Graham, M.J. Alcorn, and C. Laird Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3 Blood 97 2001 720 728
27. X. Jiang, A. Lopez, T. Holyoake, A.C. Eaves, and C.J. Eaves Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia Proc Natl Acad Sci USA 96 1999 12804 12809
28. D.G. Peters, K.M. Klucher, R.C. Perlingeiro, S.K. Dessain, E.Y. Koh, and G.Q. Daley Autocrine and paracrine effects of an ES-cell derived, BCR-ABL-transformed hematopoietic cell line that induces leukemia in mice Oncogene 20 2001 2636 2646
29. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, and S. Fanning Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
30. S.B. Marley, M.W. Deininger, R.J. Davidson, J.M. Goldman, and M.Y. Gordon The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia Exp Hematol 28 2000 551 557
31. M.S. Holtz, M.L. Slovak, F. Zhang, C.L. Sawyers, S.J. Forman, and R. Bathia Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation Blood 99 2002 3792 3800
32. K. Bartolovic, S. Balabanov, U. Hartmann, M. Komor, A.M. Boehmler, and H.J. Buhring Inhibitory effect of imatinib on normal progenitor cells in vitro Blood 103 2004 523 529
33. A.L. Petzer, E. Gunsilius, and H.C. Duba Selective in vivo effect of imatinib mesylate on BCR-ABL+ progenitors (CFC, LTC-IC) in the bone marrow of CML patients in chronic and accelerated phase on treatment with imatinib mesylate after failure or intolerance to interferon alpha Blood 100 Suppl. 1 2002 370a
34. R. Bhatia, M. Holtz, N. Niu, R. Gray, D.J. zinder, and C.L. Sawyers Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 2003 4701 4707
35. N.G. Testa, J.H. Hendry, and G. Molineux Long-term bone marrow damage after cytotoxic treatment: stem cells and microenvironment N.G. Testa R.P. Gale Hematopoiesis: long-term effects of chemotherapy and radiation 1988 Marcel Dekker Inc. New York 75 91
36. G. Martinez-Jaramillo, E. Gomez-Morales, E. Sanchez-Valle, and H. Mayani Severe hematopoietic alterations in vitro, in bone marrow transplant recipients who develop graft-versus-host disease J Hematother Stem Cell Res 10 2001 347 354
37. M.Y. Gordon, S.B. Marley, J.L. Lewis, R.J. Davidson, D.X. Nguyen, and F.H. Grand Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM J Clin Invest 102 1998 710 715
38. J.J. Cornelissen, R.E. Ploemacher, B.W. Wognum, A. Borsboom, A. Hagemeijer, and B. Lowenberg An in vitro model for cytogenetic conversion in CML: interferon-α preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture J Clin Invest 102 1998 976 983
39. R. Bathia, J.B. McCarthy, and C.M. Verfaillie Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia Blood 87 1996 3883 3891
40. E. De Maeyer, and J. De Maeyer-Guignard Interferons A. Thomson The cytokine handbook 1994 Academic Press 265 288
41. M.J. Aman, U. Keller, G. Derigs, M. Mohamadzadeh, C. Huber, and C. Peschel Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist Blood 84 1994 4142 4150
42. G. Bug, M.J. Aman, T. Trette, C. Huber, and C. Peschel Induction of macrophage-inflammatory protein-1alpha (MIP-1alpha) by interferon-alpha Exp Hematol 26 1998 117 123
43. G.R. Angstreich, B.D. Smith, and R.J. Jones Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant Curr Opin Oncol 16 2004 95 99